Roivant Sciences Ltd. (NASDAQ:ROIV) Director Sells $10,354,320.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Financial Lp Qvt sold 876,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $11.82, for a total transaction of $10,354,320.00. Following the transaction, the director now owns 22,179,358 shares in the company, valued at $262,160,011.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Roivant Sciences Stock Performance

NASDAQ ROIV opened at $11.48 on Friday. The business has a fifty day moving average of $11.50 and a 200-day moving average of $11.08. The company has a quick ratio of 27.91, a current ratio of 27.91 and a debt-to-equity ratio of 0.05. The stock has a market cap of $8.48 billion, a price-to-earnings ratio of 2.27 and a beta of 1.25. Roivant Sciences Ltd. has a fifty-two week low of $8.24 and a fifty-two week high of $13.24.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The company had revenue of $55.10 million for the quarter, compared to the consensus estimate of $30.72 million. During the same quarter last year, the firm posted ($0.38) earnings per share. Roivant Sciences’s revenue was up 155.1% on a year-over-year basis. As a group, analysts predict that Roivant Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ROIV. Bank of America raised their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research report on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Thursday, September 19th. Piper Sandler raised their price objective on Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.39.

Hedge Funds Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. Rubric Capital Management LP lifted its position in Roivant Sciences by 81.0% during the fourth quarter. Rubric Capital Management LP now owns 19,000,000 shares of the company’s stock valued at $213,370,000 after buying an additional 8,500,000 shares in the last quarter. Norges Bank acquired a new position in shares of Roivant Sciences during the 4th quarter valued at $41,506,000. Troluce Capital Advisors LLC purchased a new stake in Roivant Sciences during the 2nd quarter worth $31,182,000. First Trust Advisors LP increased its holdings in Roivant Sciences by 434.8% in the 4th quarter. First Trust Advisors LP now owns 2,739,438 shares of the company’s stock valued at $30,764,000 after purchasing an additional 2,227,192 shares in the last quarter. Finally, BlackBarn Capital Partners LP purchased a new position in Roivant Sciences in the fourth quarter valued at about $17,406,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.